[vc_row 0=””][vc_column 0=””][vc_column_text]
October 7, 2021
Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A[/vc_column_text][vc_empty_space height=”30px”][vc_column_text]
September 27, 2021
Sapreme presents Promising New Preclinical Data at 17th Annual Meeting of Oligonucleotide Therapeutics Society.[/vc_column_text][vc_empty_space height=”30px”][vc_column_text]
January 21, 2021
Sapreme Appoints Henrik Luessen as Chief Business Officer
[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space height=”30px”][vc_column_text]
October 27, 2020
Sapreme Appoints Miriam Bujny as Chief Development Officer
[/vc_column_text][vc_empty_space height=”30px”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]
September 28, 2020
[/vc_column_text][vc_empty_space height=”30px”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]
December 17, 2020
Sapreme Appoints Björn Cochlovius as Chairman of its Board of Directors
[/vc_column_text][vc_empty_space height=”30px”][/vc_column][/vc_row]